Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 105–112 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Achieve Life Sciences Inc. Cytisine - (ORCA-2) Smoking cessation NDA Filing Ongoing Oral Anti-Addiction
Achieve Life Sciences Inc. Cytisinicline - (ORCA-3) Smoking cessation of cigarettes PDUFA Ongoing Oral Anti-Addiction
Achieve Life Sciences Inc. Cytisine - (ORCA-2) Smoking cessation NDA Filing Ongoing Oral Anti-Addiction
Achieve Life Sciences Inc. Cytisinicline - (ORCA-OL) Smoking cessation for current smokers or use nicotine e-cigarettes NDA Filing Enrollment Conclusion Oral Anti-Addiction
Achieve Life Sciences Inc. Cytisinicline - (ORCA-V1) E-cigarette & vape cessation Phase 3 Trial Planned oral Anti-Addiction
Aclaris Therapeutics Inc. ATI-502 (ATI-50002-AA-201) - dose ranging Alopecia areata Phase 2 Topical Immunology
Aclaris Therapeutics Inc. ATI-502 (VITI-201 Topical) Vitiligo Phase 2 Trial Discontinued topical N/A
Aclaris Therapeutics Inc. ATI-502 (VITI-201 Topical) Vitiligo Phase 2 Trial Discontinued topical N/A